摘要:
A tilt mechanism for pivoting a vehicle body panel relative to a vehicle chassis includes a pivot pin having a pivot pin axis. The pivot pin provides a single-point pivot attachment of the body panel to the chassis such that the body panel can articulate about the pivot pin axis relative to the chassis. A support member pivotably connects to the chassis about the pivot pin axis by the pivot pin. The support member has a tilt axis along a longitudinal extent of the support member. The tilt axis is perpendicular to the pivot pin axis. The support member supports the vehicle body panel weight through a pivotal connection between a support member end and the body panel. The pivotal connection allows the body panel to pivot relative to the chassis about the tilt axis via a bearing. A torsion bar is within the support member. One portion of the torsion bar is secured to the support member and another portion is secured to the body panel by a slot that receives a torsion bar end. The torsion bar biases the body panel relative to the chassis along at least an angular portion of a pivotal range about the tilt axis. The slot is hour-glass-shaped such that the body panel can pivot about the tilt axis relative to the chassis without loading the torsion bar over a specified angular range about the tilt axis.
摘要:
An assembly for mounting a leaf spring suspension system to a vehicle. The assembly includes an arrangement of a plurality of shackles that movably secure at least a rear portion of a leaf spring, which carries an axle of the vehicle, to a frame of the vehicle.
摘要:
There are disclosed compositions for achieving reverse phase characteristics, methods of preparation thereof, and the use of amniotic tissue for cartilage repair. In an embodiment, a biocompatible articular tissue repair composition may have a therapeutic material and a carrier configured for achieving reverse phase characteristics, and methods for using the composition. In various embodiments, the therapeutic material may be amniotic tissue. In various embodiments, the carrier may be a poloxamer such as poloxamer 407. Other embodiments are also disclosed.
摘要:
There is disclosed a synthetic, composite graft to support robust bone growth. In an embodiment, the synthetic, composite graft includes a synthetic scaffold material including a material resorbable through natural cellular processes; a signaling factor combined with the scaffold material; a cell adherence factor coated on the scaffold material; a quantity of viable bone forming cells adhered to the scaffold; and a matrix substrate binding the scaffold material. There is disclosed a method of forming a synthetic, composite graft to support bone growth for bone grafting. In one embodiment, the method includes providing a synthetic scaffold material including a material resorbable through natural cellular processes; combining a signaling factor with the scaffold material; coating a cell adherence factor on the scaffold material; adhering a quantity of viable bone forming cells to the scaffold; and encasing the scaffold material with a matrix substrate. Other embodiments are also disclosed.
摘要:
There are disclosed compositions for achieving reverse phase characteristics, methods of preparation thereof, and the use of amniotic tissue for cartilage repair. In an embodiment, a biocompatible articular tissue repair composition may have a therapeutic material and a carrier configured for achieving reverse phase characteristics, and methods for using the composition. In various embodiments, the therapeutic material may be amniotic tissue. In various embodiments, the carrier may be a poloxamer such as poloxamer 407. Other embodiments are also disclosed.
摘要:
There are disclosed compositions for achieving reverse phase characteristics, methods of preparation thereof, and the use of amniotic tissue for cartilage repair. In an embodiment, a biocompatible articular tissue repair composition may have a therapeutic material and a carrier configured for achieving reverse phase characteristics, and methods for using the composition. In various embodiments, the therapeutic material may be amniotic tissue. In various embodiments, the carrier may be a poloxamer such as poloxamer 407. Other embodiments are also disclosed.